Literature DB >> 6732270

Treatment choice in acute rheumatic carditis.

D G Human, I D Hill, C B Fraser.   

Abstract

A trial was conducted using sequential analysis by pairs to compare the efficacy of corticosteroids and salicylates in the treatment of acute rheumatic carditis. The results show a significantly favourable effect of steroid treatment both in clinical response and in reduction of the erythrocyte sedimentation rate. In addition, patients receiving steroids usually had a shorter hospital stay. The use of steroids in acute rheumatic fever with carditis is recommended.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6732270      PMCID： PMC1628489          DOI： 10.1136/adc.59.5.410

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  4 in total

1.  THERAPY OF SEVERE RHEUMATIC CARDITIS. COMPARISON OF ADRENOCORTICAL STEROIDS AND ASPIRIN.

Authors:  G CZONICZER; F AMEZCUA; S PELARGONIO; B F MASSELL
Journal:  Circulation       Date:  1964-06       Impact factor: 29.690

2.  The effects of salicylate and aspirin on the activity of phosphorylase a in perfused hearts of rats.

Authors:  A E Vercesi; A Focesi
Journal:  Experientia       Date:  1977-02-15

Review 3.  Rheumatic fever in children.

Authors:  G DiSciascio; A Taranta
Journal:  Am Heart J       Date:  1980-05       Impact factor: 4.749

4.  Mitral valve replacement in children.

Authors:  D G Human; H S Joffe; C B Fraser; C N Barnard
Journal:  J Thorac Cardiovasc Surg       Date:  1982-06       Impact factor: 5.209
  4 in total
  2 in total

Review 1.  Acute rheumatic fever and streptococci: the quintessential pathogenic trigger of autoimmunity.

Authors:  Soumya D Chakravarty; John B Zabriskie; Allan Gibofsky
Journal:  Clin Rheumatol       Date:  2014-06-04       Impact factor: 2.980

2.  Treatment choice in acute rheumatic carditis.

Authors:  A Etzioni; P Vardi; J Levy; A Benderly
Journal:  Arch Dis Child       Date:  1984-12       Impact factor: 3.791
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.